Loading...
•
Jun 30, 2021
Syndax Q2 2021 Earnings Report
Syndax reported its financial results for the second quarter ended June 30, 2021 and provided a clinical and business update.
Key Takeaways
Syndax Pharmaceuticals reported a net loss of $22.9 million, or $0.44 per share, for the second quarter of 2021. The company's research and development expenses increased to $16.9 million, while general and administrative expenses decreased to $5.8 million. As of June 30, 2021, Syndax had cash, cash equivalents and short-term investments of $253.1 million.
Selected a go-forward dose for the pivotal Phase 2 portion of AUGMENT-101 based on favorable findings from the intermediate dose cohort
Initiating frontline combination of SNDX-5613 with venetoclax and azacitidine in the Beat® AML Master Clinical Trial
Enrollment ongoing in global pivotal AGAVE-201 trial of axatilimab in cGVHD; updated results from Phase 1/2 trial anticipated in 4Q21
FDA granted Fast Track Designation (FTD) to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a MLLr or NPM1 mutation
Syndax
Syndax
Forward Guidance
Syndax provided financial guidance for the third quarter and full year of 2021. Research and development expenses are expected to be $25 to $30 million for the third quarter and $90 to $100 million for the full year. Total operating expenses are expected to be $30 to $35 million for the third quarter and $110 to $120 million for the full year.